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Context: Poorly differentiated carcinomas represent an aggressive group of thyroid tumors with
controversial classification placement and poorly understood pathogenesis. Molecular data in this
group of tumors are extremely heterogeneous, possibly reflecting different inclusion criteria.
Recently homogeneous diagnostic criteria have been proposed by our group (Turin proposal) that
need to be complemented by detailed molecular characterization.
Objective: The objective of the study was to define a comprehensive molecular typing of poorly
differentiated thyroid carcinomas classified following homogeneous diagnostic criteria.
Design: Sixty-five cases of poorlydifferentiatedcarcinomaselected following theTurinproposalhave
been screened for N-, K-, H-RAS, BRAF, RET/PTC1 and 3, and PAX8/PPARmutations-rearrangements
using alternative techniques and in two different laboratories. Molecular data were compared with
clinical pathological parameters and survival by univariate and multivariate analysis.
Results: RAS mutations in codon 61 were by far the most common genetic alteration in poorly
differentiated carcinomas (23% of cases), with all mutation in NRAS except one in the HRAS gene.
A single BRAFmutationwas found in apoorly differentiated carcinomawith a residual component
of a tall cell variant of papillary carcinoma. No KRAS, RET/PTC, or PAX8/PPAR genetic alteration
was detected. In this series, the presence of RAS mutations was a unique negative prognostic
parameter at multivariate analysis.
Conclusions: The present study demonstrates that strictly classified poorly differentiated carcino-
mas are genetically homogeneous, RASmutations being the almost exclusive genetic event.More-
over, the detection of RAS mutations might be clinically relevant for the prognostic stratification
of these tumors. (J Clin Endocrinol Metab 94: 4735–4741, 2009)
Thyroid cancer is the most common type of endocrinemalignancy. The vast majority of thyroid tumors
originate from thyroid follicular cells and encompasswell-
differentiated papillary carcinoma and follicular carci-
noma. Each of these tumors can dedifferentiate and give
rise to undifferentiated (anaplastic) carcinoma. In addi-
tion to these well-established tumor entities, poorly dif-
ferentiated carcinoma has been recently added to the
World Health Organization (WHO) classification of thy-
roid tumors (1). Poorly differentiated thyroid carcinomas
comprise a heterogeneous group of tumors that occupy an
intermediate position between well-differentiated papil-
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lary/follicular carcinomas and anaplastic carcinoma from
both a histopathogenetic and a clinical point of view.
Theplacement of poorly differentiated carcinomas into
a separate classificationgroupappears justifiable basedon
large series of tumors sharing structural and/or othermor-
phological criteria that showed distinct biological and
clinical behavior (2–6). However, since the original de-
scription (7, 8), differentdiagnostic criteriahavebeenused
to define these tumors (9). Some authors defined poorly
differentiated carcinomas primarily based on the presence
of the solid, trabecular, and insular growth patterns (10),
whereas others considered the presence of high-grade fea-
tures, such as atypia, high mitotic count, and necrosis, as
a specific hallmark of these tumors (4, 11, 12), thus in-
cluding in some instances the aggressive variants of pap-
illary carcinomas (i.e. tall cell or columnar variants) in the
poorly differentiated carcinoma group.
As a result, the molecular genetic data reported to date
in the literature are limited by the heterogeneity of the case
series analyzed.Generally, irrespective of the selection cri-
teria applied,RASpointmutationsappear tobeacommon
molecular alteration in these tumors, although they have
found with highly variable frequency and wide variation
in specific types of RAS mutations (13–15). The same
holds true for the prevalence of BRAF mutations, which
have been detected in poorly differentiated carcinomas
having residual papillary carcinoma foci (16, 17) but not
in cases lacking the morphologic evidence of transition
between well-differentiated and poorly differentiated car-
cinoma (18). Similarly, RET/PTC1 rearrangements have
been found in a fraction of poorly differentiated carcino-
mas having the nuclear features of papillary carcinoma
and/or some (residual) foci of papillary carcinoma (19).
Controversial findings have been published concerning
the presence of -catenin mutations in poorly differenti-
ated carcinomas because these were detected in 0 (20) and
32% (21) of tumors analyzed in the two studies. PAX8/
PPAR rearrangements have not been reported in poorly
differentiated thyroid carcinomas so far toourknowledge.
Taken together, these molecular data indicate that
poorly differentiated carcinomas may be related to both
well-differentiated follicular and papillary carcinoma lin-
eages, which is also supported by their morphological fea-
tures, although distinct molecular pathways of progres-
sion are still poorly understood (22).
In 2004 poorly differentiated carcinoma has been in-
troduced for the first time as a separate entity in theWHO
classification of thyroid tumors (1), providing bases for
the use of uniform terminology and diagnostic criteria. An
international conference has recently proposed a diagnos-
tic algorithm based on the interpretation of the WHO
criteria, offering a uniform, consensus approach for clas-
sification of these tumors (23). The relevance of this ap-
proach has been recently tested and confirmed by a Jap-
anese group that used the proposed algorithm to identify,
among a large series of thyroid malignancies originally
diagnosed as papillary carcinomas, a homogeneous group
of tumors with unfavorable prognosis (24).
In this study, we report the results of our analysis of
molecular alterations in a large series of poorly differen-
tiated carcinomas defined according to criteria of the
WHO classification refined by the Turin conference.
Materials and Methods
Case selection
Sixty-five cases of poorly differentiated thyroid carcinoma
were selected from the databases of theDivisions of Pathology of
the University of Turin (54 cases) and University of Cincinnati
(11 cases) and included in the study.All cases havebeen classified
according to the WHO diagnostic criteria refined by the Turin
conference (23) and subdivided into poorly differentiated car-
cinomas of papillary type (PD-PTC; 19 cases) based on the
presence of residual papillary carcinoma component (eight of
19) or convoluted nuclei (eight of 19) and poorly differenti-
ated carcinomas not otherwise specified (PD-NOS; 46 cases)
in the absence of the former features. xInclusion criteria were
the availability of representative hematoxylin and eosin sec-
tions for histological review and paraffin blocks for immu-
nohistochemistry and molecular testing. Six additional cases
meeting the diagnostic criteria of poorly differentiated carci-
noma and having tissuematerial availablewere excluded from
the study due to unsatisfactory quality of DNA and RNA
isolated. The study has been approved by the Institution Re-
view Board of San Luigi Hospital.
Immunohistochemistry
In 44 cases, p53 immunohistochemistry was performed ac-
cording to standard automated immunohistochemical proce-
dure (Dako Autostainer, Glostrup, Denmark). Monoclonal an-
tibodyagainst p53 (1:200;Neomarkers, Fremont,CA)wasused.
Immunoreactions were revealed by a biotin-free dextran-chain
detection system (Envision; DakoCytomation, Glostrup, Den-
mark) and developed using diaminobenzidine as the chromogen.
Molecular analysis
Nucleic acid isolation
Genomic DNA was isolated from formalin-fixed, paraffin-
embedded tissues using the standard proteinase K-phenol-chlo-
roform extractionmethod. RNAwas isolated from paraffin em-
bedded material using the high pure RNA paraffin kit (Roche,
Mannheim, Germany) following the manufacturer’s instruc-
tions.Thequantityof isolatedDNAandRNAwasassessedusing
a Biophotometer (Eppendorf, Hamburg, Germany).
Point mutation analysis
The presence of BRAF V600E and K601E,NRAS codon 61,
HRAS codon 61, and KRAS codons 12 and 13 point mutations
was analyzed using two different techniques.
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All cases were analyzed by pyrosequencing in the laboratory
of Turin. PCR and sequencing primers were designed using the
PSQAssay Design Software version 1.0.6 (Biotage AB, Uppsala,
Sweden). One primer of each pair has a 5-biotin label necessary
for post-PCR processing. The primer sequences, amplicon sizes
and annealing temperatures are shown in Table 1. PCR ampli-
fication for the pyrosequencing assay was performed according
to standard protocols. The amplicons were mixed with sequenc-
ing primers and sequencing was performed using a PyroGold
reagent kit (Biotage AB) according to the manufacturer’s proto-
col. Results were analyzed using the PSQ-96MA 2.0.2 software
(Biotage).
In addition, the same mutations were analyzed in 40 ran-
domly selected tumors using Light Cycler PCR (Roche, India-
napolis, IN) and melting curve analysis as previously described
(25) in the laboratory of Cincinnati.
Direct nucleotide (Sanger) sequencing
All samples that testedpositive formutationswithoneorboth
techniques were sequenced using BigDye terminator kit on the
ABI3100 (Applied Biosystems, Foster City, CA) to confirm the
presence and type of mutation.
Detection of rearrangements
RET/PTC1, RET/PTC3, and PAX8/PPAR rearrangements
were detected from RNA by RT-PCR with primers designed to
flank the respective fusion point. Quality of RNA in each sample
was assessed by amplification of the -2 microglobulin gene.
Primers and PCR conditions used in this study have been previ-
ously described in detail (25). In 40 cases, the analysis was per-
formed in parallel in two laboratories (M.P. and Y.E.N.).
Controls
DNA and RNA samples from tumors or cell lines known to
carry a specific mutation or rearrangement were used as a pos-
itive control.
Statistical analysis
The correlation between genetic alterations and known clin-
ical pathological parameters was assessed by 2 test. Univariate
survival analysis was based on the Kaplan-Meier product limit
estimate of overall survival distribution. Unadjusted differences
between survival curveswere testedusing theLogRank test using
P 0.05 as the level of significance. Multivariate analysis of the
relative impact on survival of each parameter included in the
univariate analysis was estimated using the Cox proportional
hazards regressionmodel. Statistical analysis was performed us-
ing the Prism 4 (GraphPad, San Diego, CA) and SPSS softwares
(Chicago, IL).
Results
Molecular profile
The molecular alterations detected in 65 poorly differ-
entiated carcinomas are summarized in Table 2.
RAS mutations represented by far the most common
genetic alteration in poorly differentiated carcinomas, en-
countered overall in 15 of 65 cases (23%). All but one
mutation were in the NRAS gene, codon 61, with theGln
to Arg (Q61R, CAA  CGA) substitution (Fig. 1). The
remaining tumor had the HRASQ61Kmutation. Nomu-
tation was detected in the KRAS gene. The frequency of
RASmutations was slightly higher in PD-PTC type (seven
of 19 cases) than in PD-NOS (eight of 46 cases), although
the difference was not statistically significant (2 test, P
0.285). The prevalence of RAS mutations was not signif-
icantly different in cases of poorly differentiated carci-
noma from Turin compared with those from Cincinnati
(13 of 54 and two of 11 cases, respectively; P  0.761).
The commonV600E BRAFmutation was encountered
in a single case of poorly differentiated carcinoma, which
showed a minor component of papillary carcinoma, tall
cell variant.
Light Cycler PCR and pyrosequencing methods pro-
vided identical results of mutation detection in all cases
except one case of NRAS mutation, which was not
detected by pyrosequencing but confirmed by direct
sequencing.
RET/PTC types 1 and 3 and PAX8/PPAR transloca-
tions were absent in all cases.
TABLE 1. PCR and sequencing primer sequences, annealing temperatures, and amplicon length in pyrosequencing
analysis
Gene Codons Forward PCR primer Reverse PCR primer Sequencig primer Ann. T Product size (bp)
BRAF NM_004333 600–601 B/CTTCATAATGCTTGCTCTGATAGG GCATCTCAGGGCCAAAAA CCACTCCATCGAGATT 54 C 235
NRAS NM_002524 61 B/TGAAACCTGTTTGTTGGACATACT CGCAAATGACTTGCTATTATTGA CATGGCACTGTACTCTTCT 55 C 130
HRAS NM_005343 61 GGTCATTGATGGGGAGACGTG B/CGCATGGCGCTGTACTCCT CATCCTGGATACCGC 57 C 72
KRAS NM_033360 12–13 B/CTGAATATAAACTTGTGGTAGTTGG ATATTCGTCCACAAAATGATTCT AGGCACTCTTGCCTA 57 C 92
B, Biotinylation site; Ann, annealing; T, temperature.
TABLE 2. Summary of genetic alterations in poorly
differentiated thyroid carcinomas
Poorly differentiated
carcinoma type
(number of
cases analyzed) RAS BRAF
RET/PTC
1 and 3
PAX8/
PPAR
Overall (65) 15/65 1/65 0/65 0/65
PD-PTC-type (19) 7/19 1/19
Type of mutation NRAS Q61R (6)
H61Q61K (1)
V600E (1)
PD-NOS (46) 8/46 0/46
Type of mutation NRAS Q61R (7)
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Correlation between the presence of RAS
mutations and clinical pathological parameters
The status of RAS mutation was compared with the
various clinical and pathological characteristics of poorly
differentiated carcinomas in the present series. The female
to male ratio was 2.2:1, mean age was 62.1 yr (range
23–86), and the mean tumor diameter was 5.6 cm (range
1.5–12). Up to two thirds of the cases presented with high
pathological tumor stage (68% stage  pT3) and 38%
had extrathyroidal extension. Predominant oncocytic fea-
tures, defined by the morphological recognition of large
cells characterized by abundant deeply eosinophilic and
granular cytoplasm in more than 75% of the neoplastic
cell population (1) in tumors otherwise fulfilling the Turin
proposal for the diagnosis of poorly differentiated carci-
noma (23), were observed in 17 cases (26%). Pathological
N stage was available in 11 cases only and was not con-
sidered in the correlation analysis. Finally, follow-up in-
formation were available for 53 cases. More than half of
them (53%) had tumor recurrence or were dead of the
disease at the time of last follow-up (mean follow-up time:
52 months, range 4–228). None of the above-mentioned
characteristicswasdifferentially expressed in the cohortof
patients from Italy compared with those from the United
States (all P  0.05).
None of the parameters considered, including gender,
age, size, pT, extrathyroidal extension, and predominant
oncocytic features, was significantly associatedwithRAS-
positive genotype.
The prevalence of RASmutations had a tendency to be
higher in cases with low/absent p53 protein expression,
although without statistical significance (P  0.196).
Despite the lack of association betweenRASmutations
and specific disease characteristics, a univariate analysis
demonstrated a strong correlation with shorter overall
survival in patients harboring RAS mutation (P 0.004)
(Fig. 2). The negative prognostic impact ofRASmutations
was confirmedby amultivariate analysis,which identified
this mutations as the only independent prognostic indica-
tor in the current series of poorly differentiated carcino-
mas (Table 3).
Discussion
Since the original description of poorly differentiated car-
cinomas as a separate entity among malignant thyroid tu-
mors, several tumor series have been reported, although
based on different and sometimes controversial criteria.
The variability in diagnostic criteria has relevance and
reproducibility of molecular data generated in the litera-
ture to date on this type of aggressive thyroid tumors. In
fact, it is more than likely that molecular studies per-
formedover the last 2 decades included tumors that donot
meet the currentWHO definition of poorly differentiated
carcinoma. In this study,weperformedmolecular analysis
of a large, homogeneous series of poorly differentiated
thyroid carcinomas selected using the strict Turin criteria
(23). Our data indicate that RASmutations constitute the
most common genetic alteration in these tumors. With
regard to specific mutation hot spot, NRAS mutations at
codon61wereby far themost common.These findings are
in agreement with previous data in the literature on the
FIG. 1. Molecular profile of a poorly differentiated thyroid carcinoma
(A) with residual component of follicular variant of papillary carcinoma
(A, top, and B) and predominant solid component with extensive
necrosis (A, bottom, and C), showing by means of pyrosequencing
analysis the presence of wild-type NRAS in the normal peritumoral
thyroid (D) and heterozygous mutation at codon 61 in the tumor
(E; reverse sequence showing the presence of an additional peak
corresponding to the NRAS Q61R-CAA  CGA-substitution).
FIG. 2. Overall survival analysis of 53 poorly differentiated carcinomas
according to RAS mutation status.
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occurrenceofNRASmutations, although the reported fre-
quency ranged from about 18% to more than 60% (13,
14). By contrast,we could not confirm the high prevalence
of KRAS mutations observed by another group (15, 17)
because no mutations could be detected in our series by
two different methods. Interestingly, in our series RAS
mutations did not correlatewith specific clinical or patho-
logical parameters but were strongly associatedwith poor
prognosis. This suggests that RAS mutation detection
might be clinically relevant for the prognostic stratifica-
tion of these generally more aggressive thyroid tumors
because it allows the separation of those poorly differen-
tiated carcinomas that are particularly prone to more ag-
gressive behavior. From a methodological point of view,
both the techniques used in the present paper seem to be
adequate for RAS mutational screening in poorly differ-
entiated thyroid carcinomas, although Light Cycler PCR
methods showed a slightly higher sensitivity.
Concerning papillary carcinoma-related molecular al-
terations, such as BRAF mutations and RET/PTC trans-
locations,we observed only a single BRAFmutation of the
former in a case associated with a residual component of
papillary carcinoma, tall cell variant. These data are in
partial contrast with previous studies that found a higher
occurrence of both alterations in a subset of cases having
residual nuclear and/or architectural features of papillary
carcinoma (16–19). Although technical and/or geograph-
ical differences might act to explain such discrepancy, it
should be critically considered that more restrictive inclu-
sion criteria applied in the present study could have neg-
atively selected papillary carcinoma variants (such as
solid), formerly included in the poorly differentiated tu-
mor group.
From an histopathogenetic point of view, the absence
of papillary carcinoma-related molecular alterations in
our series of poorly differentiated carcinomas does not
rule out the hypothesis of their possible dedifferentiation
from preexisting papillary carcinoma; rather it possibly
suggests that progression from papillary to poorly differ-
entiated carcinoma is restricted to those cases harboring
RAS mutation (26) and is different from the molecular
pathway leading to the progression of papillary to ana-
plastic carcinoma, in which BRAF mutations have been
found in up to 25% of cases (27, 28). Noteworthy, com-
parableRASmutation rateswere observed in caseswithor
without predominant oncocytic features, thus suggesting
that phenotypical andmolecular signatures leading to on-
cocytic transformation are independent and, possibly,
parallel to the molecular alterations involved in poorly
differentiated carcinoma onset. Moreover, we could not
detect any PAX8/PPAR translocation in our series of
cases, thus suggesting that follicular carcinomas with
PAX8/PPAR rearrangements typically do not undergo
dedifferentiation, as also suggested by the absence of this
particular alteration in anaplastic carcinomas (29).
Despite a significant prevalence ofRASmutation,more
than 70% of cases in our series had no identifiable mo-
lecular alterations, indicating that other genes must be
involved. Potential candidates are TP53 and PIK3CA. Re-
garding TP53, there are several reports (30, 31) on the
presence of TP53 mutations in a small fraction of poorly
differentiated carcinomas. In the present series, up to 30%
of cases showedapositiveTP53protein expression,which
is expected to correlate with the presence of gene muta-
tion. However, the positive stainingwas usually restricted
to less than 20% of cells, arguing against the importance
of TP53 alteration in pathogenesis of this type of cancer.
With respect to PIK3CA, its mutations or genomic ampli-
fications have been found in a subset ofwell-differentiated
carcinomas, particularly in follicular carcinomas (32), and
its role in the molecular progression of thyroid cancer is
suggested by recent studies in anaplastic carcinoma (27,
33). This may warrant further studies of PIK3CA alter-
ations in poorly differentiated carcinomas.
Additional candidate genes may be identified using
wide screening genomic and expression profiling technol-
ogies, although the few reported studies that included
TABLE 3. Multivariate analysis of overall survival in
poorly differentiated thyroid carcinomas according to
clinicopathological parameters and RAS mutation status
Variable HR 95% CI P
Sex
Female
Male 2.397 0.802–7.164 0.117
Age (yr)
45
45 0.695 0.126–3.825 0.676
Size
4
4 0.000 Undefined 0.986
Oncocytic
features
Absent
Present 0.000 0.000–6.174 0.967
PD type
PTC type
NOS type 1.301 0.433–3.907 0.638
pT stage
pT1–2
pT3–4 0.000 Undefined 0.986
Extrathyroidal
extension
Absent
Present 1.077 0.266–4.346 0.916
RAS mutation
Absent
Present 3.670 1.085–12.412 0.036
HR, Hazard ratio; CI, confidence intervals.
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poorly differentiated carcinomas failed to demonstrate
additional specific alterations in these tumors (34, 35).
In conclusion, the present study represents the most
comprehensive genetic profiling of poorly differentiated
thyroid carcinomas diagnosed according to the WHO
classification under strict selection criteria, which demon-
strates that, among the most common known genetic al-
terations in thyroidmalignancies, theRAS genemutations
represent the most common genetic event in poorly dif-
ferentiated carcinomas.Moreover,RASmutations appear
to bear prognostic information, identifying a subset of
more aggressive tumors within the group.
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